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SUMMARY: 
AIMS: Current-induced vasodilation (CIV) is an axon-reflex response observed during 
monopolar current application such as iontophoresis. Cyclo-oxygenase derivates (COD) 
participate in CIV and act as sensitizing agents at the anodal level. Mechanisms involved 
during cathodal current application (CCA) are partially unknown. In a randomized double 
blinded crossover trial, we tested in sixteen healthy subjects (i) the influence of the inter-
stimulation interval (I-I) by comparing CIV following all-at-once 10 s CCA against 2x5 s 
CCA with intervals ranging 15 s-16 min, (ii) the participation of COD in CIV using 1g 
aspirin or placebo intake.  
METHODS: Measurements were repeated 2 h and 14 days after treatment. Laser Doppler 
flowmetry assessed cutaneous blood flow, reported in multiple of baseline.  
RESULTS: Before treatment, peak vasodilation 10 min after the last current application 
(CVCstim2) increased compared to baseline whatever the I-I. Increase in CVCstim2 from 
baseline was greater for the 4 min (9.4 (5.3, 10.9) times; median (1rst percentile, 3
rd
 
percentile)) and higher I-Is compared to all-at-once delivery (3.0 (2.1, 4.3) times, p<0.05). 
The response was similar after placebo but aspirin abolished this vasodilation (increase by 1.2 
(1.1, 1.3) times for all-at-once delivery and by 1.5 (1.3, 1.7) ± 0.3 times for 4 min interval, 2 
h after aspirin intake) that was recovered after 14 days.  
CONCLUSIONS: This confirms the participation of COD in CIV with CCA and their 
sensitizing action. This model can represent an attractive way to study the axon-reflex and 
sensitizing function of COD in humans.  
What is already known about this subject: 
-Monopolar current applications (segmented or not) at the cutaneous level can elicit 
vasodilatation. 
-Cyclo-oxygenase derivates (propably prostaglandins) participate in this phenomenon and, 
during segmented current applications, can have a sensitizing effect on the nervous afferent 
stimulated. 
-This effect is well known at the anodal level but must be better described for cathodal 
current.  
 
What this study adds: 
-Participation of cyclo-oxygenase derivates is confirmed for cathodal segmented current 
application. 
-A minimal interval must be respected between two current applications to observe the 
sensitizing effect of cyclo-oxygenase derivates.  
-This model is usefull to study the sensitizing function of cyclo-oxygenase derivates in 
humans. 
 
 
 
INTRODUCTION: 
Monopolar current application as those performed during iontophoresis can elicit a current-
induced vasodilation (CIV) at the skin microcirculation level [1, 2]. This phenomenon is 
considered an adverse effect of the technique since CIV can possibly make confused the 
interpretation of the effect of the drug applied through iontophoresis [2]. This response is 
assumed to result from an axon reflex because it is abolished under local anesthesia or after 
chronic capsaicin desensitization [3]. Among the different mechanisms involved in CIV, 
Gohin et al. (2011) showed that prostacyclin (PGI2), a potent vasodilator produced by the 
vascular endothelium participates in CIV in healthy rat skin [4]. Furthermore, it has been 
revealed that for the same amount of electrical charge, segmented current application leads to 
a greater CIV than all-at-once delivery [5]. Despite the fact that this phenomenon has been 
observed both at the anode and at the cathode, it has been poorly described at this latter level. 
However, some observations confirmed that this mechanism of sensitization is aspirin-
sensitive suggesting the involvement of cyclo-oxygenase derivates (COD) (probably 
prostaglandins) [5, 6].  
It has been previously reported that the recovery of CIV after aspirin intake and following 
segmented cathodal or anodal current delivery was long lasting, since sensitization is still 
abolished or dramatically reduced two days after aspirin intake [5, 6]. Such results suggest 
that COD are a major factor in the development of CIV promoting vasodilation either directly 
or through a mechanism of sensitization. We consider that this mechanism likely represents 
an interesting physiological model of the role of COD as neural sensitizing agent and 
deserves that we focus on it. 
It has been previously observed, for anodal segmented current application and an 
interstimulation interval shorter than 10 min, a sensitization mechanism based on COD [5].  
Yet, whereas Durand et al. (2002) observed an influence of the length of the interstimulation 
interval on the amplitude of sensitization at the anode, Tartas et al. (2005) did not report any 
change in CIV amplitude whatever the interstimulation interval (10, 20 or 40 min) at the 
cathode [6]. The reason for this discrepancy remains unclear but could rely on a long lasting 
effect of the mediators of sensitization. 
Consequently, we screened whether a minimal interval (inferior to 10 min) during cathodal 
segmented current application was required to lead to amplification of CIV compared to all-
at-once delivery. We crossed these measurements with aspirin or placebo intake to confirm 
the involvement of COD in CIV in the responses observed before and at 2 hours and 14 days 
after a single oral dose of 1g aspirin or placebo.  
 
METHODS: 
Population 
Sixteen healthy subjects participated in the study. The local ethics committee 
approved the study. All volunteers provided written, informed consent prior to participation. 
This study was carried out in accordance with the Declaration of Helsinki. It is registered to 
the American National Institutes of Health database under reference No: NCT 01572961. 
None of the investigators involved in the clinical and microvascular assessments were aware 
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in Figure 1. Before each microvascular assessment, subjects were asked to refrain from 
consuming caffeine in the four hours preceding the test. After baseline microvascular 
assessment (i.e. standard response), subjects were randomly assigned to either one single-
dose of Aspirin (Aspégic adulte 1g; Sanofi-Aventis®) dissolved in 125 ml of orange juice or 
orange juice alone. Two hours and 14 days after the allocation, microvascular assessments 
were repeated and a global wash out period of 14 days was respected before the protocol was 
repeated [7]. 
 
Subjects’ preparation 
Participants were placed supine in a quiet room with the ambient temperature set at 
23±1°C, and left at rest for 15 min before each experiment for temperature and 
cardiovascular adaptations [8]. 
 
Assessment of skin microcirculation: 
For microvascular recordings, we studied successively skin blood flow on the volar 
aspect of both forearms using laser Doppler flowmetry (LDF). On each forearm, different 
probes were used. “A                ” were specifically designed to allow for simultaneous 
blood flow recording and current application, and are refer           “                 ”  
(probe 481-1, Perimed, Sweden) (Figure 2 . T   “      ”                                b   
of ∼1 cm2 allowing for the positioning of the specially designed disposable sponge for 
iontophoresis. At the center of the sponge, skin LDF was measured through a multifiber laser 
probe (780 nm, 1 mW maximal emission, and bandwidth for Doppler shift 20–20,000 Hz). A 
third electrode (PF408, Perimed, Jarfalla, Sweden) was used as a reference to confirm the 
absence of response to the current application at an adjacent unstimulated site, and to account 
for eventual systemic variations. The electrodes were placed at different points on the 
forearm, each measured area being at a minimal distance of 4 cm from each of the others. 
All the probes were connected to laser Doppler flowmeters (Periflux PF 4001, and 
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suppliers (Periiont micropharmacology System, PF 382 Perimed, Jarfalla, Sweden). For those 
electrodes, a disposable adhesive electrode (Kendall) was positioned 5 cm away from the 
laser probes, forming the anode and closing the current system [9] (Figure 2). 
The changes of skin blood flow in response to cathodal current application of 0.1 mA, 
through deionized water, were recorded on each forearm and expressed in perfusion unit (PU) 
or multiple of baseline. The current application was delivered on each active probe either all-
at-once (10 s) or in two consecutive 5-s applications with different intersimulation intervals. 
Four different intervals were tested: 15 s (1/4 min), 30 s (1/2 min), 1 min, 2 min, 4 min, 8 min 
and 16 min. The procedure is described on Figure 3. 
Cardiovascular and temperature recordings 
Blood pressure was continuously recorded from the left middle finger (Finapres, 
Ohmeda, Madison, WI, USA) with mean arterial pressure (MAP) obtained from the 
continuous blood pressure signal. The MAP signal was recorded at a sampling rate of 18 Hz 
using an analog to digital converter (MP100, Biopac sys, Goleta, USA) and analyzed offline 
using the Acknowledge® software V3.5.4 (Biopac sys, Goleta, USA). 
Local skin temperature was measured using a surface thermocouple probe positioned 
5 cm from any of the other electrodes [8]. The thermocouple was connected to an electronic 
thermometer (BAT-12, Physitemp Instruments, Inc., Clifton, NJ, USA). 
 
Data and statistical analyses 
Results are presented as mean  SD, and for CVC, mediane (1rst percentile, 3rd 
percentile). Cutaneous temperature was expressed in °C.  
Results for raw data were expressed in CVC or in multiple of baseline CVC values. 
CVC was calculated as the ratio of cutaneous blood flow to mean arterial pressure (mmHg) 
and expressed in PU/mmHg [10].  
The values recorded before placebo or aspirin intake have been considered as the 
standard response. 
For further analysis, the following points were determined for each subject and 
measurement: 
- mean reference CVC (average of the CVC values during the first min of the 
reference period, CVCref),  
- CVCstim2 corresponding to the CVC values 10 min after the end of the second 
current application for the segmented current applications or 10 min after the 
10s current application during all-at-once delivery. 
Parametric or non parametric tests were performed according to the distribution of 
values using SPSS (IBM SPSS statistics V15.0, Chicago, USA). Differences in CVCref and 
CVCstim2 were analyzed via the test of Wilcoxon using. Increases in CVCstim2 from baseline in 
function of the delivery mode and the interstimulation interval were compared via repeated 
measures ANOVA. When a significant difference was found, Tukey post hoc analysis was 
performed. For each statistical analysis, a two-       p       ≤  . 5 w              
significant. 
 
 
RESULTS: 
Subjects were 22 ± 2 years old (10 males, 6 females). Mean weight and height were 
68.1 ± 9.4 kg and 172.8 ± 9.5 cm, respectively. At the beginning of the protocol, their blood 
characteristics were the following: glycemia: 4.6 ± 0.5 mmol/L, LDL cholesterol: 2.7 ± 0.6 
mmol/L, HDL cholesterol: 1.5 ± 0.3 mmol/L, creatinemia: 73.3 ± 9.2 µmol/L and number of 
platelets: 247.6 ± 49.8 (giga/L). 
There was no significant change in cutaneous temperature during the measurement, 
whatever the day considered. Mean skin temperature ranged between 33.8 ± 1.5 to 34.6 ± 1.1 
°C. 
Table 1 presents the CVC values (CVCref and CVCstim2) recorded in standard 
conditions, i.e. before any kind of treatment, and the CVC values observed after placebo or 
aspirin intake depending on the delivery mode of current application (10 s or 2 x 5 s with 
various intervals).  
In standard condition, i.e. before treatment, CVC increased significantly from 0.08 (0.06, 
0.11) to 0.22 (0.13, 0.42) PU/mmHg following an all-at-once 10 s continuous current 
application. When the current application was segmented (i.e. 2x5 s with different intervals), 
CVC also increased significantly from baseline whatever the interval considered. However, 
CVCstim2 was significantly greater when the total current charge was segmented compared to 
all-at-once delivery when the interval between the two 5 s current application was at least of 
4 min. For example, CVC increased by 3.1 (2.5, 5.8) times for a 2x5 s current application 
with an interval of 1 min (non significant (NS) vs. all-at-once delivery). On the contrary, it 
increased by 9.4 (5.3, 10.9) times with an interval of 4 min (p<0.05 vs. all-at-once delivery). 
We did not observe any change in CVCstim2 amplitude when the interstimulation interval 
ranged between 4 and 16 min (p=NS). 
Placebo treatment did not affect significantly the responses observed in standard conditions 
and the values recorded 14 days after placebo intake were not different from the standard 
response (Table 1). 
Intake of 1g aspirin resulted in the disappearance of CIV following the all-at-once 10 s 
current application (Table 1). Two hours after intake, CVCref was 0.09 (0.06, 0.012) 
PU/mmHg and CVCstim2 was 0.11 (0.07, 0.15) PU/mmHg (NS vs. CVCref). Aspirin also 
abolished the CIV induced by segmented current application whatever the interval considered 
and there was no difference in CVCstim2 between the continuous 10 s current application and 
the segmented current application. For example, CVC increased by 1.2 (1.1, 1.3) times for all 
at once 10 s current application and by 1.5 (1.3, 1.7) times for a segmented current 
application with a 4 min interval.  
Fourteen days after aspirin intake, values recorded were not different from those recorded 
before the treatment. Again, after current application (all at once or segmented), CVC 
increased significantly from baseline (Table 1). In addition, increase in CVCstim2 was 
significantly greater when the total current charge was segmented compared to all-at-once 
delivery when the interstimulation interval between was 4 min and more. CVC increased by 
3.9 (3.4, 9.7) times for a 2 x 5 s current application with an interval of 2 min (NS vs. all at 
once); but it increased by 8.0 (5.9, 10.9) (p<0.05 vs. all at once) with an interval of 4 min. 
We did not observe any change in CVC all along the different microvascular assessments at 
the reference probe (laser probe 3 on the right forearm and laser probe 4 on the left forearm). 
 
DISCUSSION: 
This study confirms that segmented application of cathodal low intensity (0.10 mA) 
current leads to a significant and greater vasodilation in healthy human skin compared to the 
one observed when the current total charge is applied all-at-once. This suggests that the first 
current application can activate a sensitization mechanism that is abolished by aspirin. The 
magnitude of this sensitization mechanism relies on the length of the interstimulation interval 
and a minimum of 4 minutes is necessary to observe a significant sensitization mechanism. 
Due to its sensitivity to aspirin, this mechanism likely relies on the release of prostaglandins. 
CIV is probably based on an axon reflex [2, 11] but the mechanisms participating in 
CIV with all-at-once or segmented cathodal current application are not perfectly known [3]. 
CIV in response to anodal or cathodal current application (whatever the delivery mode) is 
abolished by aspirin suggesting the involvement of COD (prostaglandins?) in the vasodilator 
mechanism [5, 6]. Gohin et al. confirmed the participation of PGI2 in the CIV in response to 
a single prolonged (240 s) current application in rat skin [4]. PGE2 and PGI2 are powerful 
vasodilators on their own but prostaglandins are also able to sensitize the response of afferent 
unmyelinated fibres in animal [12, 13]. 
We previously hypothesized the participation of COD in the neural sensitization to 
anodal current application [5]. This would explain the amplified CIV observed for an amount 
of electrical charge delivered segmented compared to all-at-once [5]. This hypothesis was 
comforted latter at the cathodal level by the observation of Tartas et al. [6]. Durand et al. in 
supplementary material brought initially the evidence that this mechanism of sensitization 
was long lasting since still occurring 90 min after the first current application but yet its 
intensity was declining with time [5]. Using segmented current application (two sequences of 
anodal current, 0.1mA, 1 min with interstimulation interval of 5, 10, 20, 40, 60 or 90 min), 
we observed that the maximal amplification was observed for the 5 min interval at the anodal 
level and progressively diminished with time. We hypothesized that the initial anodal current 
application had lead to the release of prostaglandins acting as sensitizing agent on the neural 
fibres involved in CIV leading to a large CIV when current application is repeated and that 
the progressive catabolism of prostaglandins would explain the blunting of this sensitizing 
mechanism [5]. At the cathodal level, the CIV is usually more important than the CIV at the 
anodal level for the same intensity and duration of current application [3]. Consequently, 
Tartas et al. used shorter segmented current application (two sequences of cathodal current, 
0.10 mA, 10 s with interstimulation interval of 10, 20 or 40 min) to investigate the presence 
or not of the mechanism of sensitization at the cathodal level [6]. This mechanism was 
observed again with an amplitude in CIV, for a given total electric charge, superior when the 
current application was segmented compared to all-at-once. However, the authors did not 
report any difference in CIV amplitude whatever the interval considered. Considering the fact 
that cathodal current applications elicit more CIV than anodal current, this observation could 
be explained by an important and long lasting release of prostaglandins during the first 
current application leading to an important and long lasting mechanism of sensitization. 
However, some questions remain concerning this mechanism. 
In the aim to better characterize this mechanism of sensitization at the cathodal level, 
we used half of the amount of electrical charge used by Tartas et al. (i.e. in our study two 
sequences of cathodal current, 0.10 mA, 5 s) and proposed shorter interstimulation interval 
(from 2 min to 16 min) [6]. The hypothesis here was that a minimal interval was necessary to 
have the mediators of sensitization released. We observed that after the second current 
application, a significant amplification of CIV, compared to CIV measured after a single all-
at-once 10 s cathodal current application, appears for an intersimulation interval of 4 min. 
This amplification was abolished 2 hours after aspirin intake whatever the interstimulation 
interval considered. This result confirms what has been described for segmented anodal 
current application. Indeed, we previously reported a disappearance of CIV following 2 x 
1min current applications with a 10 min interstimulation interval 2 hours after aspirin intake 
[5]. COD like prostaglandins are known to act as sensitizing agent and to be aspirin sensitive. 
It is likely that the same kind of COD participate in the mechanism of sensitization at the 
anode and at the cathode. Consequently we hypothesized that a single 5 s cathodal current 
application is sufficient to induce a significant release of COD acting as sensitizing agents 
when a cathodal current application is repeated. A minimal delay between two monopolar 
current applications has to be respected to observe the sensitizing effect of COD leading to 
amplification of CIV (4 min in our experimental conditions). The exact nature of these COD 
remains to be determined. 
In conclusion, several tests exist to investigate cutaneous vasomotor function. For 
example, post occlusive reactive hyperemia stimulates both the endothelial and the non-
endothelial pathway [14, 15]. Sodium nitroprusside and acetylcholine iontophoresis 
investigate the non-endothelial and the endothelial pathways, respectively [9, 10, 16, 17]. 
Gohin et al. proposed to use CIV to investigate the vascular function of prostacyclin in rats 
[4]. We confirm the involvement of COD in CIV and the existence of a sensitizing 
mechanism leading to amplification of CIV when cathodal current application is repeated. 
The same observation has been previously made for segmented anodal current application. 
This suggests that the study of CIV in response to segmented anodal or cathodal current 
application, when the appropriate charge is applied and a minimal interstimulation interval 
respected, can be an attractive way to study the neural sensitizing function of 
microcirculation in humans. 
Limits 
This study has been conducted in young and healthy subjects. We cannot exclude a 
change in the amplitude and mechanisms in other populations such as elderly people, diabetic 
subjects or patients suffering from cardiovascular disease. Furthermore, to guarantee the 
same cardiovascular state for determination of CVC, all measurements (i.e. the tests of the 
different interstimulation intervals) have been performed during the same experimental 
session on the two arms. It could be consequently hypothesized that the different current 
applications performed could interfere one over another on a same arm and that the responses 
could differ between the two arms. However, sites of current applications on the forearms 
were randomized and the current was locally applied. There is no report of a difference in 
CIV in function of the arm (left or right), there was no change in CVC at the reference probe 
and we clearly observed an influence of the interstimulation interval on the apparition of 
CIV. All these elements lead us to the conclusion that there was no interference between the 
different current applications. 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
CIV: Current Induced Vasodilation 
CVC: Cutaneous Vascular Conductance 
COD: Cyclo-Oxygenase Derivates 
PGE2: Prostaglandin E2 
PGI2: Prostaglandin I2 
NS: Non Significant 
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 Fig. 1: Design of the study. D0 means day of treatment. H2 means time of measurement 2 
hours after treatment, D14 means time of measurement 14 days after treatment.  
 Fig. 2: Experimental setup (for clarity, only one arm is presented) 
 Fig. 3: Protocol 
 
